Position
Bridgewater in Sarepta Therapeutics, Inc.
Back to the book · All holders of SRPT
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$508.9K$21.76 → $17.97
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 280.6K | $6.04M | — | — | — | 0.0% |
| Q1 2026 | 134.3K | $2.92M | $21.76 | $32.2K | −$3.15M | 0.0% |
| Q2 2026 | 152.1K | $2.73M | $17.97 | −$508.9K | $319.7K | 0.0% |